NHI reimbursement approved MSD's Syprine

MSD Korea has obtained the NHI reimbursement approval for Syprine (trientine hydrochloride) for the treatment of Wilson's disease, a rare disease, under the tradename of "MSD trientine" effective from Feb. 1. Syprine was registered as an orphan drug in 2005, which has been classified as a common therapeutic drug with the name of "MSD trientine" under the NHI coverage through pharmacies and hosp...